Development of plasmid-mediated resistance in Vibrio cholerae during treatment with trimethoprim-sulfamethoxazole.
The persistence of Vibrio cholerae, biotype el tor, in a patient treated with trimethoprim-sulfamethoxazole was due to the acquisition of a conjugative resistance plasmid. The plasmid, with a molecular size of 72 megadaltons, belonged to incompatibility group 6-C and conferred resistance to ampicillin, chloramphenicol, sulfonamide, and trimethoprim.
D002701:Chloramphenicol / Q000494:pharmacology; D002771:Cholera / Q000188:drug therapy; D003227:Conjugation, Genetic; D004338:Drug Combinations / Q000494:pharmacology / Q000627:therapeutic use; D004352:Drug Resistance, Microbial; D004926:Escherichia coli / Q000201:enzymology; D005243:Feces / Q000382:microbiology; D006801:Humans; D011815:R Factors; D013420:Sulfamethoxazole / Q000494:pharmacology / Q000627:therapeutic use*; D014295:Trimethoprim / Q000494:pharmacology / Q000627:therapeutic use*; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D014734:Vibrio cholerae / Q000187:drug effects* / Q000235:genetics; D001618:beta-Lactamases / Q000378:metabolism
D004338:Drug Combinations; D002701:Chloramphenicol; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D014295:Trimethoprim; D001618:beta-Lactamases; D013420:Sulfamethoxazole